Daiichi Sankyo acquires first US packaging facility
This article was originally published in Scrip
In another small step towards full independence in a critical market, Daiichi Sankyo is spending $10.3 million on what will be its first in-house pharmaceutical packaging facility in the US.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.